GCM
AKBA icon

Graham Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Graham Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Sell
207,759
-40,593
-16% -$48.3K ﹤0.01% 980
2026
Q1 		$345K Sell
248,352
-128,212
-34% -$176K 0.01% 764
2025
Q4 		$606K Buy
376,564
+146,588
+64% +$307K 0.01% 557
2025
Q3 		$628K Buy
229,976
+191,817
+503% +$638K 0.01% 534
2025
Q2 		$139K Buy
38,159
+20,606
+117% +$56.6K ﹤0.01% 1179
2025
Q1 		$33.7K Buy
+17,553
New +$35.8K ﹤0.01% 1241
2024
Q3 		– Sell
-57,624
Closed -$58.8K – 1077
2024
Q2 		$58.8K Buy
57,624
+28,838
+100% +$35.6K ﹤0.01% 981
2024
Q1 		$52.7K Buy
28,786
+5,153
+22% +$8.24K ﹤0.01% 1010
2023
Q4 		$29.3K Buy
+23,633
New +$24.1K ﹤0.01% 950
2023
Q3 		– Sell
-26,586
Closed -$24.3K – 994
2023
Q2 		$24.3K Buy
+26,586
New +$25.7K ﹤0.01% 929

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Graham Capital Management's AKBA Position: Q2 2026 in Review

Graham Capital Management reduced its Akebia Therapeutics (AKBA) stake by 16% in Q2 2026, selling an estimated $48.3K and leaving 207,759 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Graham Capital Management first reported a position in AKBA in Q2 2023 and has held it in 10 quarters since. The position peaked at $628K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Graham Capital Management held 207,759 shares of Akebia Therapeutics worth $237K as of Q2 2026.
  • Graham Capital Management sold 40,593 Akebia Therapeutics shares in Q2 2026, an estimated $48.3K.
  • Akebia Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #980 holding.
  • Graham Capital Management first reported a position in Akebia Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • Graham Capital Management's Akebia Therapeutics position peaked at $628K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.